Clinical trial
A Multicenter, Prospective, Non-interventional Observation Study to Evaluate the Safety and Effectiveness of OAD Triple Therapy in Korean Type 2 Diabetic Mellitus Patients
NCT06838286 is registered in ClinicalTrials.gov with Chong Kun Dang Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Prospective, Non-interventional Observation Study to Evaluate the Safety and Effectiveness of OAD Triple Therapy in Korean Type 2 Diabetic Mellitus Patients
- Lead sponsor
- Chong Kun Dang Pharmaceutical
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- January 2, 2024
- Completion date
- December 31, 2029
- Enrollment
- 10,000 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.